Cancer is responsible for over 8 million deaths worldwide. Based on 2010-2012 data, about 39.6% of men and women will be diagnosed with cancer during their lifetime. Although substantial progress has been made, its incidence and prevalence is continuously increasing. Therefore, the implementation of non-invasive massive population screening programs is needed to reduce its mortality. Indeed, 90% of the 8 most common cancer type patients can be eff ectively cured if early diagnosed. Among other biomarkers, the humoral immune response has been demonstrated useful for early cancer diagnosis, predating the diagnosis to the development of clinical symptoms. Cancer autoantibodies have been shown useful as clinical biomarkers for reliable diagnosis, prognosis and therapy monitoring. Despite the advantages of autoantibody detection for cancer diagnosis, the fact that patients develop autoantibodies to multiple tumor-associated antigens (TAAs) is a major limitation to get clinically validated assays because on the one hand autoantibody diagnostic panels should be accurately identifi ed and on the other hand, new immunoassays for simultaneous multiplexed autoantibody detection should be developed. In this context, we have developed two proof-of-concept immunoassays focused on the screening of the humoral immune response of cancer patients and based on fusion proteins from the p53 loop that could help with early cancer detection: a luminescence self-assembled ELISA for the characterization of the diff erent isoforms of the p53 loop in cancer that has permitted to identify two new TAAs in cancer, and an electrochemical biosensor able to detect p53 autoantibodies in serum based on HaloTag fusion proteins easily adaptable for point-of-care detection of cancer patients.

Resumen del póster presentado al 1st Joint Meeting of the French-Portuguese-Spanish Biochemical and Molecular Biology Societies y al XL Spanish Society of Biochemistry and Molecular Biology (SEBBM) Congress, celebrado en Barcelona (España) del 23 al 26 de octubre de 2017.-- et al.

Peer reviewed